Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612216 | 0.86 | HRH3 (0.56) | CHRNA7CHRNB2CHRNA4HRH3KDM4E | |
| SCHEMBL13995242 | 0.83 | HRH3 (0.53) | CHRNA7CHRNB2CHRNA4HRH3KDM4E | |
| SCHEMBL6174357 | 0.83 | ALDH1A1 (0.51) | ADRA1DADRA1AADRA1B | |
| SCHEMBL12090225 | 0.80 | CHRNB2 (0.62) | CHRNA7CHRNB2CHRNA4HRH3CHRM2 | |
| SCHEMBL14983619 | 0.77 | CHRNA7 (0.55) | CHRNA7CHRNB2CHRNA4HRH3KDM4E | |
| SCHEMBL21937561 | 0.72 | KDM4E (0.60) | CHRNA7CHRNB2CHRNA4HRH3KDM4E | |
| SCHEMBL27364546 | 0.70 | ADRA1D (0.50) | ADRA1DADRA1AADRA1B | |
| SCHEMBL12090436 | 0.70 | CHRM2 (0.64) | CHRNA7CHRNB2CHRNA4HRH3KDM4E | |
| SCHEMBL703479 | 0.70 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL31375369 | 0.70 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324064-A1 | NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786147-B2 | Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders | Medical College of Georgia Research Institute. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20050227993-A1 | Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | 2005-10-13 | — | — | US | disclosed |
| WO-2003008559-A2 | NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324064-A1 | NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERS | CDR2, CHAT, CHRNA2 | CHRNA7 33/4885CHRNB2 4/4885CHRNA4 9/4885 |
| US-20050227993-A1 | Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders | CDR2, CHAT, CHRNA2 | CHRNA7 33/4885CHRNB2 4/4885CHRNA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.